Education
About Us
Working with TipRanks
Follow Us
Enveric Biosciences (ENVB)
NASDAQ:ENVB
ENVB Stock Chart & Stats
$3.72
-$0.12(-23.95%)
At close: 4:00 PM EST
$3.72
-$0.12(-23.95%)
Day’s Range― - ―
52-Week Range$1.96 - $37.19
Previous CloseN/A
Volume362.16K
Average Volume (3M)781.31K
Market Cap
$3.27M
Enterprise Value-$2.35M
Total Cash (Recent Filing)$3.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.81
Shares Outstanding1,390,335
10 Day Avg. Volume899,153
30 Day Avg. Volume781,309
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.35
Enterprise Value/Market Cap-0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.66
Enterprise Value/Ebitda0.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-315
Revenue Forecast (FY)$10.00M
Bulls Say, Bears Say
Bulls Say
Pipeline AdvancementThe successful completion of toxicology studies for EB-003 marks a significant milestone, advancing the drug closer to clinical trials. This progress strengthens Enveric's pipeline, potentially leading to future revenue through commercialization or partnerships.
No DebtEnveric's absence of debt reduces financial risk, offering a buffer against financial instability. This positions the company to potentially leverage future financing opportunities without the burden of existing debt obligations.
Intellectual PropertyReceiving a notice of allowance for EVM401 strengthens Enveric's intellectual property portfolio. This enhances the company's competitive edge and potential for future licensing deals, which could lead to revenue generation.
Bears Say
No RevenueThe lack of revenue generation since 2020 highlights a critical challenge for Enveric. Without income, the company remains reliant on external financing, which may not be sustainable long-term, threatening its financial viability.
Negative Cash FlowConsistently negative operating cash flow indicates Enveric's inability to generate cash from its operations. This ongoing cash burn could limit the company's ability to invest in R&D and sustain operations without additional financing.
Ongoing LossesPersistent losses reflect operational challenges and unprofitability, which can erode shareholder equity and limit strategic flexibility. This ongoing financial strain poses a risk to Enveric's long-term sustainability and growth prospects.
Enveric Biosciences News
ENVB FAQ
What was Enveric Biosciences’s price range in the past 12 months?
Enveric Biosciences lowest stock price was $1.96 and its highest was $37.19 in the past 12 months.
What is Enveric Biosciences’s market cap?
Enveric Biosciences’s market cap is $3.27M.
When is Enveric Biosciences’s upcoming earnings report date?
Enveric Biosciences’s upcoming earnings report date is Mar 26, 2026 which is in 24 days.
How were Enveric Biosciences’s earnings last quarter?
Enveric Biosciences released its earnings results on Nov 14, 2025. The company reported -$10.81 earnings per share for the quarter, missing the consensus estimate of N/A by -$10.81.
Is Enveric Biosciences overvalued?
According to Wall Street analysts Enveric Biosciences’s price is currently Overvalued.
Does Enveric Biosciences pay dividends?
Enveric Biosciences does not currently pay dividends.
What is Enveric Biosciences’s EPS estimate?
Enveric Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enveric Biosciences have?
Enveric Biosciences has 1,390,335 shares outstanding.
What happened to Enveric Biosciences’s price movement after its last earnings report?
Enveric Biosciences reported an EPS of -$10.81 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.297%.
Which hedge fund is a major shareholder of Enveric Biosciences?
Currently, no hedge funds are holding shares in ENVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enveric Biosciences
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
GT Biopharma
―
Artelo Biosciences
―
Ownership Overview
13.68% Insiders
0.17% Mutual Funds
1.22% Other Institutional Investors
83.71% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---